BUPROPION HCL XL TABLET (EXTENDED-RELEASE)

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

BUPROPION HYDROCHLORIDE

Tilgjengelig fra:

BAUSCH HEALTH, CANADA INC.

ATC-kode:

N06AX12

INN (International Name):

BUPROPION

Dosering :

300MG

Legemiddelform:

TABLET (EXTENDED-RELEASE)

Sammensetning:

BUPROPION HYDROCHLORIDE 300MG

Administreringsrute:

ORAL

Enheter i pakken:

7/90

Resept typen:

Prescription

Terapeutisk område:

MISCELLANEOUS ANTIDEPRESSANTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0131140004; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2021-09-16

Preparatomtale

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BUPROPION HCL
XL
Bupropion Hydrochloride Extended-Release Tablets
Tablet (extended-release), 150 mg, 300 mg, For oral use
USP
Antidepressant
Bausch Health, Canada Inc.
2150 St-Elzear Blvd. West
Laval, Quebec
H7L 4A8
Submission Control Number: 270781
Date
of Initial Authorization:
SEP 16, 2021
Date of Revision:
FEB 3, 2023
_ _
_Pr_
_BUPROPION HCL XL Product Monograph Page 2 of 59_
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS
01/2023
7 WARNING AND PRECAUTIONS
, Immune
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL
CHANGES……………………………………………………..…………2
TABLE OF CONTENTS
...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
.............................................................................................................
4
1.2
Geriatrics…………………………………………………………………………………………………………….4
3
SERIOUS WARNINGS AND PRECAUTIONS
BOX………………………………………………………..…5
2
CONTRAINDICATIONS
................................................................................................
5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
..................................................... 5
4.4
Administration
............................................................................